Cocrystal Pharma, Inc. (COCP) to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that President and interim CEO Sam Lee, Ph.D. and CFO and interim CEO James Martin will present a company overview in the Noble Capital Markets Virtual Roadshow Series presented by Channelchek. The live presentation will be by webcast on Wednesday, December 8, 2021 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time). Registration for the webcast presentation is available here.

The Cocrystal company overview will be followed by a question-and-answer session moderated by Noble Capital Markets Senior Research analyst Robert LeBoyer and will feature questions submitted by the audience. A replay of the webcast will be available within three business days of the live presentation.

“We are working diligently toward initiating clinical studies in 2022 with two promising COVID-19 protease inhibitors,” said Dr. Lee. “Our antiviral inhibitors have shown broad-spectrum activity in vitro against COVID-19 and its variants, including the now predominant Delta variant. We further intend to use our unique structure-based technology platform to demonstrate antiviral activity against newly emerging variants such as Omicron, which is more complex given its many mutations.”

Cocrystal is waiting for response from the FDA on its pre-Investigational New Drug (IND) briefing packaging for CDI-45205, its COVID-19 protease inhibitor for intranasal/pulmonary delivery. The company plans to submit a second briefing package to the FDA, this one for its orally administered COVID-19 protease inhibitor, in the first half of 2022. In a third COVID-19 program, Cocrystal is using its unique structure-based technology platform to discover COVID-19 replication inhibitors for oral administration.

About Noble Capital MarketsNoble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 36 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. More information is available at www.noblecapitalmarkets.com or via email at [email protected].

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Gaucho Group Holdings Inc. (VINO) Receives Nasdaq Non-compliance Notice
• IBM (IBM) to Acquire HashiCorp (HCP) for $35/sh Cash or $6.4B